DISCOVERED: The Key to Unlocking New Treatments for Inflammatory Diseases?

Have you ever heard of histone deacetylases, or HDACs for short?

Don’t worry if you haven’t—these tiny proteins aren’t exactly household names. But for millions of people living with inflammatory bowel disease (IBD) and other inflammatory conditions, HDACs could hold the key to a brighter, healthier future.

In a groundbreaking new study, researchers from the Icahn School of Medicine at Mount Sinai have uncovered exactly how a specific family of HDACs, known as class IIa HDACs, control the behavior of immune cells that drive inflammation in the body.

And their findings could pave the way for new, more effective treatments for a wide range of inflammatory diseases.

So, what exactly are HDACs, and why do they matter?

Think of them as tiny control switches inside our cells. They help regulate which genes are turned on or off at any given time, kind of like a conductor directing a symphony.

In the case of class IIa HDACs—specifically HDAC4 and HDAC7—their main job is to oversee the development of a type of immune cell called Th17 cells. These cells are like the body’s built-in security system—they help fight off invading bacteria and viruses by producing a powerful inflammatory molecule called interleukin-17 (IL-17).

But sometimes, Th17 cells can get a little too enthusiastic about their job… When they start pumping out too much IL-17, it can lead to chronic inflammation and damage to healthy tissues.

That’s where conditions like IBD, which includes ulcerative colitis and Crohn’s disease, come into play.

The Mount Sinai team wanted to find out exactly how HDAC4 and HDAC7 control the activity of Th17 cells. Using advanced laboratory techniques, they discovered that these HDACs work together in a delicate balance to fine-tune the genes that drive Th17 cell development and IL-17 production.

But here’s the really exciting part: when the researchers used a special compound to block the activity of HDAC4 and HDAC7 in mice with colitis (a type of IBD), they saw a significant reduction in Th17 cell activity—and inflammation in the gut.

This suggests that targeting class IIa HDACs could be a promising new approach to treating IBD and other inflammatory diseases. By dialing down the activity of these master control switches, we may be able to rein in overactive Th17 cells and restore balance to the immune system.

Of course, the journey from laboratory discovery to real-world treatment is a long and complex one. The Mount Sinai team’s findings are just the first step in a much larger process.

But armed with this new understanding of how class IIa HDACs work at the cellular level, researchers are now better equipped to design more selective and effective HDAC inhibitors that could one day help millions of people with inflammatory diseases live healthier, more comfortable lives.

In the meantime, if you or a loved one is living with IBD or another inflammatory condition, it’s important to work closely with your healthcare team to manage your symptoms and maintain the best possible quality of life. This may include a combination of medications, dietary changes, stress management techniques, and other lifestyle modifications.

And as always, stay tuned to the latest research developments—you never know when the next big breakthrough might be just around the corner.

To scientific breakthroughs,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

Sources:

https://medicalxpress.com/news/2024-04-scientists-cellular-functions-family-proteins.html